Southeast Asia Information Port News (www.dnyxxg.com) – The Guangxi Zhuang Autonomous Region Medical Security Bureau announced on the 22nd that Guangxi will build and utilize the China-ASEAN Regional Pharmaceutical Transaction (Centralized Procurement) Platform (hereinafter referred to as the "Platform") effectively, actively promoting cooperation with ASEAN countries in the field of "small but beautiful" public healthcare services, and expanding new scenarios for cross-border medical insurance services.
The 2026 Guangxi Medical Security Work Conference was held in Nanning on the 22nd. Zhang Yi, Director of the Guangxi Zhuang Autonomous Region Medical Security Bureau, stated at the conference that in 2026, Guangxi will leverage its geographical advantages and rely on major international exchange activities such as the China-ASEAN Expo to further promote in-depth exchanges between the Platform and ASEAN countries on medical insurance policies and pragmatic cooperation in pharmaceutical transactions.
The aforementioned Platform is China's first cross-border regional pharmaceutical transaction platform, jointly built by the National Healthcare Security Administration of China and Guangxi. It is an international regional pharmaceutical service trade and settlement platform open to ASEAN and SCO countries.
Currently, the platform has achieved significant progress, with 224 domestic pharmaceutical companies and 19 overseas companies joining the platform. It has registered 3,438 types of medicines and medical consumables intended for sale to ASEAN countries. The first cross-border online transaction between Hangzhou Sino-American East China Pharmaceutical and Qilu Pharmaceutical and an ASEAN company was successfully completed, achieving seamless integration of the entire process of cross-border drug purchase, settlement, and delivery. On January 13th of this year, the platform's transaction volume exceeded 10 million RMB.
Zhang Yi stated that Guangxi will leverage its medical insurance data advantages to continuously optimize the platform's full-process service capabilities, including matchmaking, negotiation, transaction, settlement, transportation, and credit supervision, providing cost-reduction and efficiency-enhancing transaction services support for domestic and foreign pharmaceutical companies, and accelerating the "going global" of Chinese pharmaceuticals and medical devices. (End)
